Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × dolasetron × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 1 Neoplasms 1 Nausea 1

Interventions

Cyclophosphamide 751 Carboplatin 653 Paclitaxel 608 Bevacizumab 598 pembrolizumab 578 Cisplatin 567 Gemcitabine 510 Docetaxel 479 Radiotherapy 462 Rituximab 454 Dexamethasone 412 Nivolumab 380 Doxorubicin 370 Capecitabine 325 Fluorouracil 324 Etoposide 302 Pemetrexed 279 Oxaliplatin 278 Cytarabine 276 Prednisone 266 Lenalidomide 264 Erlotinib Hydrochloride 259 fludarabine phosphate 258 Leucovorin 250 Trastuzumab 244 fludarabine 244 Bortezomib 237 Vincristine 237 Filgrastim 230 Cetuximab 224

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01636947 2018-09-25

KMEC

Merck Sharp & Dohme LLC

Phase 4 Completed

494 enrolled 14 charts

Nausea, Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon ⚡